RARE
NASDAQUltragenyx Pharmaceutical Inc.
Price$21.42-0.37 (-1.70%)
01:30 PM07:30 PM
News · 26 weeks74-35%
2025-12-142026-06-07
Mix4190d
- Insider20(49%)
- Other10(24%)
- SEC Filings8(20%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- PRUltragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare ConferenceNOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical comp
- INSIDERChief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- PRUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company's common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). T
- INSIDERDirector Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Ray Amrit was granted 7,751 shares, increasing direct ownership by 33% to 31,116 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Sanders Corazon (Corsee) D. was granted 7,751 shares, increasing direct ownership by 51% to 23,095 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Narachi Michael was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Welch Daniel G was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Dunsire Deborah was granted 7,751 shares, increasing direct ownership by 25% to 38,566 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SECUltragenyx Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- SECSEC Form SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.SCHEDULE 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)
- PRUltragenyx to Participate at Bank of America's 2026 Healthcare ConferenceNOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America's 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pha
- INSIDEREVP and Chief Medical Officer Crombez Eric sold $8,586 worth of shares (344 units at $24.96), decreasing direct ownership by 0.31% to 111,189 units (SEC Form 4) to cover taxes4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SECUltragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- PRUltragenyx Reports First Quarter 2026 Financial Results and Corporate UpdateFirst quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 GTX-102 for Angelman syndrome: New longer-term data from Phase 1/2 clinical study support durable and improving effects across multiple domains; Phase 3 data expected in the second half of 2026 NOVATO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel
- INSIDERChief Financial Officer Horn Howard sold $116,607 worth of shares (4,683 units at $24.90), decreasing direct ownership by 4% to 110,342 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SECSEC Form DEFA14A filed by Ultragenyx Pharmaceutical Inc.DEFA14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- PRUltragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate UpdateNOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 5, 2026, to discuss its financial results and corporate update for the quarter ending March 31, 2026. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica
- INSIDERSVP, Chief Accounting Officer Huizenga Theodore Alan was granted 20,241 shares, increasing direct ownership by 42% to 68,911 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- PRUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 36,447 restricted stock units of the company's common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)
- INSIDERSEC Form 4 filed by Kakkis Emil D4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERSEC Form 4 filed by Huang Dennis Karl4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERSEC Form 4 filed by Pinion John Richard4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERSEC Form 4 filed by Parschauer Karah Herdman4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
RARE FAQ
7 questionsWhat does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation...Where does RARE stock trade?
Ultragenyx Pharmaceutical Inc. (RARE) is listed on NASDAQ.What sector and industry is RARE in?
Ultragenyx Pharmaceutical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ultragenyx Pharmaceutical Inc. go public?
Ultragenyx Pharmaceutical Inc. (RARE) completed its IPO in 2014.What are analysts saying about RARE?
Ultragenyx Pharmaceutical Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $2500.00 price target on 2026-03-24. Recent price targets cluster around $2500.00.What companies are similar to RARE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RARE side-by-side with any of them on Quantisnow.How can I track RARE on Quantisnow?
Quantisnow aggregates Ultragenyx Pharmaceutical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RARE to receive live email and push alerts on every new disclosure.